Phase 3 CLL Survival Analysis Selected for ASH Press Briefing
BERKELEY HEIGHTS, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Genta
Incorporated (Nasdaq: GNTA) announced that several abstracts related to the
Company's clinical programs will be featured at the annual meeting of the
American Society of Hematology (ASH) in Atlanta, GA during December 7-11,
2007. Programs involving Genasense(R) (oblimersen sodium) Injection,
Genta's lead anticancer compound, and G4544, a new oral drug for bone
diseases, were released in abstracts published in the meeting proceedings,
-- Addition of oblimersen (Bcl-2 antisense) to
fludarabine/cyclophosphamide for relapsed/refractory chronic
lymphocytic leukemia extends survival in patients who achieve CR/nPR:
Results from a randomized Phase 3 study.
Oral session: Tuesday, December 11, 2007; 7:30 am
Note: This abstract has been selected for a featured press briefing
sponsored by ASH on Sunday December 9 at 9:30 am.
-- Oblimersen (Genasense(R)), a phosphorothioate Bcl-2 antisense
oligonucleotide (ASO), can be safely administered by bolus subcutaneous
(SC) injection and brief IV Infusion. Publication.
-- Phase 1 assessment of G4544, an orally bioavailable formulation of
gallium nitrate. Publication.
Genasense inhibits production of Bcl-2, a protein made by cancer cells
that is thought to block chemotherapy-induced apoptosis (programmed cell
death). By reducing the amount of Bcl-2 in cancer cells, Genasense may
enhance the effectiveness of current anticancer treatment. Genta is
pursuing a broad clinical development program with Genasense
|SOURCE Genta Incorporated|
Copyright©2007 PR Newswire.
All rights reserved